411: Capricor's data clash and a fugitive in ...

What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Re ...  Show more

On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more

Pharma stocks breaking out, as President Trump inks a drug pricing deal. What it means for the group, and how the broader health care sector is breathing a sigh of relief. Plus Elon Musk and some bingeing backlash. Why the billionaire is calling for customers to cancel their s ...

Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information ab ...  Show more

Do you have a real relationship or just a non-binding letter of intent? (00:21) Nick Sciple and Mary Long discuss: - The S&P’s turnaround and inflation’s slow month-over-month decline. - A stock pop from a nuclear reactor company that doesn’t have a working nuclear reactor. - Pri ...  Show more